The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I agree that It really does feel that a licencing deal could be announced very soon. What is particularly exciting is that approx 50% of pharma pipelines are now being externally sourced these days. This is why well heeled HNWI & PI's are at last tuning in to Sareum. This is brilliant news for Sareum shareholders.
Another key point to remember is that x 1 from here takes the share price to 18p and then the following x 1 to 36p etc. i.e. It is not inconceivable that Sareum's share price could be over 20p soon.
Should have said
That's what I think Ahfam.
That's what u think Ahfam. Covid is kind of a loss leader. The big prize is autoimmune but in the Covid casino. Any company that licences it off us will probably increase in value because of it.
Licence for Covid is favourite and YES even pre-clinical.
Remember this from the 2018 finals RNS, before Covid19 and the grant, before we got the US Army Lupus validation and before we got the extra patents- Dr Reader has since tweaked 1801 to perfection and we are at zenith point chaps and we are superior than Dex and Bari (as has tox issues and mentioned below).
The BOD were confident back then pre-covid now they must be uber confident and so should we as the science has got better and 1802 also has worldwide patent protection.
Sareum believes SDC-1801 represents a strong candidate entering an area of increasing industry interest with substantial clinical validation. The Company's view has been formed based on the progress of molecules in clinical development by Bristol-Myers Squibb (BMS-986165; TYK2 inhibitor) and Pfizer (PF-06700841; TYK2/JAK1 inhibitor) in psoriasis and other autoimmune diseases, which has been promising but also shown signals that suggest there is an opportunity for a molecule with best-in-class properties.
Furthermore, several licensing deals for preclinical and clinical-stage assets have been completed recently in the sector with highly attractive economic terms, such as:
· TD-1473 (a pan-JAK inhibitor) - licensed by Janssen from Theravance (2018) at the end of Phase 1 studies for $100M cash up-front, up to $900M in milestone payments, plus royalties*
· Filgotinib (JAK1 inhibitor) - licensed by Gilead from Galapagos (2015) at the end of Phase 2 trials for $300M cash and $425M equity investment up-front, up to $1,350M in milestone payments, plus 20%+ royalties*
· Undisclosed TYK2 inhibitor (plus other assets) - Celgene formed an alliance with Nimbus Therapeutics (2017) in preclinical stage for undisclosed up-front and milestone payments
Approved products targeting the JAK family with blockbuster sales potential, despite warnings based on side effects related to JAK2/JAK3 activity, include:
· Xeljanz® tofacitinib (Pfizer) (JAK1/JAK3 inhibitor) - approved for rheumatoid and psoriatic arthritis and ulcerative colitis, with 2017 sales of $1.35Bn*, despite black box warnings for serious infections and lymphoma
· Olumiant® baricitinib (Eli Lilly) (JAK1/JAK2 inhibitor) - approved from rheumatoid arthritis, with expected peak sales of approximately $1Bn*, but with black box warnings for serious infections, lymphoma and thrombosis
· Jakafi® ruxolitinib (Incyte/Novartis) - approved for myelofibrosis and polycythemia vera (a type of blood cancer) with 2017 sales of $1.1Bn* despite warnings of infections and blood cell counts
The scale of the deals and sales delivered/forecast for these candidates and products targeting TYK2 and related JAK family members gives Sareum confidence in the exciting, high value market opportunity for SDC-1801.
*Sources include company information and analyst consensus as reported in BioWorld "FDA approves Lilly and Incyte's baricitinib for second-line RA treatment"
Thank You Glen, yes still big numbers.
Ahfam, good post (as always).
Just a minor correction. The Kymab/Sanofi deal was for $1.45 billion (not GBP).
https://www.globenewswire.com/news-release/2021/01/11/2155914/0/en/Sanofi-to-acquire-Kymab-adding-KY1005-to-its-pipeline-a-human-monoclonal-antibody-targeting-key-immune-system-regulator-OX40L.html
"Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones." Just wanted to clarify for the sake of accuracy. We're still talking big numbers, though!
Tim was talking about $800m deal for Tyk2 just auto-immune back in 2014/15 I believe.
That was all before.
- We got more patents for it,
- before Dr Reader tweaked it perfection creating 1802 cancer,
- before 1802 got US patent which completed worldwide patent protection in a Tyk2 cancer market we have no competition in,
- before US Army Lupus validation,
- before covid and Tyk2 Covid validation,
- before covid grant and Dr Parker saying 'Initial studies, using isolated human lung cells, are encouraging and show that SDC-1801 does indeed downregulate the increase in cytokines believed to be responsible for ARDS and the cytokine storm following infection with SARS-CoV-2'
- before we got superior to dex and bari (as bari has tox issues)
So $800m is not going to cut it anymore, that will be probably the upfront payment now- we have Dr Michael Owen who co-founded and was chief scientific officer of Kymab which was sold to Sanofi in January for £1.5bn.